Back to top
more

Beam Therapeutics (BEAM)

(Delayed Data from NSDQ)

$19.12 USD

19.12
1,587,919

+0.29 (1.54%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $19.13 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3.85% and -38.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Vir Biotechnology (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

by Ekta Bagri

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

Zacks Equity Research

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Innovation ETF (ARKK) Hits New 52-Week High

by Sweta Killa

Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.

Ekta Bagri headshot

3 Promising Genomics Stocks to Keep an Eye On in 2025

by Ekta Bagri

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

Sundeep Ganoria headshot

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

by Sundeep Ganoria

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.

Ekta Bagri headshot

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

by Ekta Bagri

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

Sundeep Ganoria headshot

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?

by Sundeep Ganoria

CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.

Zacks Equity Research

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

by Zacks Equity Research

Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.

Sundeep Ganoria headshot

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

by Sundeep Ganoria

CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.

Ekta Bagri headshot

3 Top Genomics Stocks to Add to Your Portfolio in 2025

by Ekta Bagri

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

Zacks Equity Research

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

by Zacks Equity Research

Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.

Zacks Equity Research

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

by Zacks Equity Research

INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.

Zacks Equity Research

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

by Zacks Equity Research

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.

Zacks Equity Research

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.

Zacks Equity Research

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.

Zacks Equity Research

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

by Zacks Equity Research

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.

Zacks Equity Research

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

by Zacks Equity Research

IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.

Zacks Equity Research

Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains

by Zacks Equity Research

VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.

Zacks Equity Research

Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised

by Zacks Equity Research

MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.

Zacks Equity Research

Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

by Zacks Equity Research

AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.

Zacks Equity Research

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

by Zacks Equity Research

CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.

Zacks Equity Research

Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down

by Zacks Equity Research

APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.